| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 2,398 | 3,999 | 5,435 | 6,525 |
| Restricted cash security deposit | 50 | 50 | 50 | 50 |
| Prepaid expenses and other current assets | 367 | 26 | 168 | 693 |
| Total current assets | 2,815 | 4,075 | 5,653 | 7,268 |
| Leasehold improvements and equipment net | 138 | 138 | 156 | 158 |
| Assets held for sale - net | NaN | NaN | 70 | 70 |
| Operating lease right-of-use assets net | 457 | 531 | 1,351 | 1,462 |
| Finance lease right-of-use assets net | 4 | 4 | 5 | 6 |
| In-process research and development | 2,260 | 2,260 | 2,260 | 2,260 |
| Restricted cash security deposit | 200 | 200 | 200 | 200 |
| Total non-current assets | 3,059 | 3,133 | 4,042 | 4,156 |
| Total assets | 5,874 | 7,208 | 9,695 | 11,424 |
| Accounts payable | 712 | 315 | 80 | 167 |
| Accrued expenses | 694 | 452 | 564 | 795 |
| Operating lease liabilities current | 718 | 694 | 846 | 817 |
| Financing lease liabilities current | 2 | 2 | 5 | 5 |
| Total current liabilities | 2,126 | 1,463 | 1,495 | 1,784 |
| Deferred tax liability | 257 | 257 | 257 | 257 |
| Operating lease liabilities net of current portion | 464 | 653 | 1,472 | 1,697 |
| Financing lease liabilities net of current portion | 5 | 5 | 11 | 11 |
| Total non-current liabilities | 726 | 915 | 1,740 | 1,965 |
| Total liabilities | 2,852 | 2,378 | 3,235 | 3,749 |
| Common stock par value 0.0001 per share, 500,000,000 shares authorized at march 31, 2026 and december 31, 2025 6,406,191 issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 1 | 1 | 1 | 1 |
| Additional paid-in capital | 215,729 | 215,616 | 215,334 | 214,399 |
| Accumulated deficit | -212,708 | -210,787 | -208,875 | -206,725 |
| Total stockholders equity | 3,022 | 4,830 | 6,460 | 7,675 |
| Total liabilities and stockholders equity | 5,874 | 7,208 | 9,695 | 11,424 |
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB)